It's been a tough year for Celgene Corp. (NASDAQ:CELG) investors, but upcoming phase 3 data on luspatercept from Acceleron Pharma (NASDAQ:XLRN) could rekindle interest in Celgene's stock price.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,